Vir Biotech Posts $80.1M Q2 Profit, 88% HDV Clearance in Key Trial
VIR has more than doubled off its 52-week low of $4.155.
Summary
Vir Biotechnology delivered a strong Q2 with $238.9M in revenue and $80.1M net income, beating the $216.5M consensus. The $1.01B cash position extends runway into H2 2028, easing near-term financing risk. SOLSTICE Phase 2 data showed the elebsiran + tobevibart combo cleared HDV RNA in 88% of patients, nearly double the 53% with monotherapy — a clear efficacy signal ahead of the pivotal ECLIPSE 1 readout in Q4 2026. This follows the CFO resignation announced in July, but the clinical momentum and cash buffer offset that uncertainty. ECLIPSE 1 data later this year is the next major catalyst.
At the time of this announcement, VIR was trading at $8.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.16 to $11.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.